Public Release: 

Results of Raltegravir plus combination antiretroviral therapy in early HIV infection

Mary Ann Liebert, Inc./Genetic Engineering News

IMAGE

IMAGE: BioResearch Open Access is a peer-reviewed open access journal led by Editor-in-Chief Robert Lanza, MD, Chief Scientific Officer, Ocata Therapeutics Headquarters, and Editor Jane Taylor, PhD. The Journal provides a... view more

Credit: ©Mary Ann Liebert, Inc., publishers

New Rochelle, NY, February 22, 2016--Addition of the integrase strand transfer inhibitor raltegravir (RAL) to standard antiretroviral therapy (ART) in ART-naive patients with early HIV infection was not associated with a difference in the quantity of HIV DNA, residual virus in the blood, or CD4+ T-cells containing replication-competent virus, according to a new study published in BioResearch Open Access, a peer-reviewed open access journal from Mary Ann Liebert, Inc., publishers . The article is available to download on the BioResearch Open Access website.

Ann Collier and a team of researchers from University of Washington and Harborview Medical Center, Seattle, and National Institute of Allergy and Infectious Diseases, Bethesda, MD, compared the effects of standard triple ART regimen to standard combination ART plus RAL over 96 weeks. They describe the study design and report their results in the article "A Pilot Study of Raltegravir Plus Combination Antiretroviral Therapy in Early Human Immunodeficiency Virus Infection: Challenges and Lessons Learned".

"The lessons learned from this pilot study will be informative to other researchers in this field, particularly in the design of future studies looking at the effects of ART in early HIV infection," says BioResearch Open Access Editor Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland.

Research reported in this publication was supported by the National Institutes of Health Award Number AI57005. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

###

About the Journal

BioResearch Open Access is a peer-reviewed open access journal led by Editor-in-Chief Robert Lanza, MD, Chief Scientific Officer, Ocata Therapeutics Headquarters, and Editor Jane Taylor, PhD. The Journal provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMed Central. All journal content is available on the BioResearch Open Access website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many areas of science and biomedical research, including DNA and Cell Biology, Tissue Engineering, Stem Cells and Development, Human Gene Therapy, HGT Methods, and HGT Clinical Development, and AIDS Research and Human Retroviruses. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.